Metropolitan Life Insurance Company (MetLife)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-21,304
| Closed | -$1.81M | – | 2527 |
|
|
2021
Q4 | $1.81M | Sell |
21,304
-365
| -2% | -$33.6K | 0.02% | 593 |
|
|
2021
Q3 | $2.08M | Sell |
21,669
-23,105
| -52% | -$2.18M | 0.03% | 482 |
|
|
2021
Q2 | $4.36M | Buy |
44,774
+22,147
| +98% | +$2.12M | 0.03% | 473 |
|
|
2021
Q1 | $2.2M | Buy |
22,627
+15,640
| +224% | +$1.64M | 0.03% | 479 |
|
|
2020
Q4 | $670K | Sell |
6,987
-136
| -2% | -$13.1K | 0.01% | 1172 |
|
|
2020
Q3 | $685K | Sell |
7,123
-185
| -3% | -$21.4K | 0.01% | 984 |
|
|
2020
Q2 | $892K | Buy |
7,308
+902
| +14% | +$99.7K | 0.02% | 804 |
|
|
2020
Q1 | $554K | Sell |
6,406
-130
| -2% | -$12.7K | 0.01% | 993 |
|
|
2019
Q4 | $703K | Sell |
6,536
-122
| -2% | -$12.8K | 0.01% | 1123 |
|
|
2019
Q3 | $600K | Buy |
6,658
+24
| +0.4% | +$2.24K | 0.01% | 1184 |
|
|
2019
Q2 | $560K | Sell |
6,634
-153
| -2% | -$12.6K | 0.01% | 1237 |
|
|
2019
Q1 | $598K | Sell |
6,787
-72
| -1% | -$6.02K | 0.01% | 1179 |
|
|
2018
Q4 | $490K | Sell |
6,859
-22
| -0.3% | -$2.11K | 0.01% | 1203 |
|
|
2018
Q3 | $846K | Sell |
6,881
-137
| -2% | -$15.5K | 0.01% | 1024 |
|
|
2018
Q2 | $689K | Buy |
7,018
+400
| +6% | +$35.8K | 0.01% | 1108 |
|
|
2018
Q1 | $549K | Buy |
6,618
+91
| +1% | +$7.68K | 0.01% | 1214 |
|
|
2017
Q4 | $506K | Sell |
6,527
-61
| -0.9% | -$4.16K | 0.01% | 1282 |
|
|
2017
Q3 | $404K | Buy |
6,588
+336
| +5% | +$17.7K | ﹤0.01% | 1826 |
|
|
2017
Q2 | $288K | Buy |
6,252
+351
| +6% | +$17K | ﹤0.01% | 2104 |
|
|
2017
Q1 | $256K | Hold |
5,901
| – | – | ﹤0.01% | 2106 |
|
|
2016
Q4 | $228K | Sell |
5,901
-267
| -4% | -$12.1K | ﹤0.01% | 2271 |
|
|
2016
Q3 | $312K | Sell |
6,168
-296
| -5% | -$14.7K | ﹤0.01% | 2038 |
|
|
2016
Q2 | $294K | Sell |
6,464
-53,312
| -89% | -$2.45M | ﹤0.01% | 2061 |
|
|
2016
Q1 | $2.36M | Buy |
59,776
+320
| +0.5% | +$12.7K | 0.02% | 844 |
|
|
2015
Q4 | $3.36M | Buy |
59,456
+581
| +1% | +$29.5K | 0.03% | 675 |
|
|
2015
Q3 | $2.34M | Buy |
58,875
+191
| +0.3% | +$9.23K | 0.02% | 850 |
|
|
2015
Q2 | $2.8M | Buy |
+58,684
| New | +$2.49M | 0.02% | 818 |
|
|
2015
Q1 | – | Sell |
-57,136
| Closed | -$1.28M | – | 2362 |
|
|
2014
Q4 | $1.28M | Sell |
57,136
-3,864
| -6% | -$73.2K | 0.01% | 1183 |
|
|
2014
Q3 | $956K | Hold |
61,000
| – | – | 0.01% | 1301 |
|
|
2014
Q2 | $905K | Buy |
61,000
+3,236
| +6% | +$45.7K | 0.01% | 1423 |
|
|
2014
Q1 | $930K | Buy |
57,764
+1,501
| +3% | +$25.7K | 0.01% | 1392 |
|
|
2013
Q4 | $525K | Hold |
56,263
| – | – | ﹤0.01% | 1786 |
|
|
2013
Q3 | $637K | Hold |
56,263
| – | – | ﹤0.01% | 1587 |
|
|
2013
Q2 | $753K | Buy |
+56,263
| New | +$691K | 0.01% | 1419 |
|
Other funds holding NBIX
BG
DM
Metropolitan Life Insurance Company (MetLife)'s NBIX Position: Q1 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 21,304 shares — an estimated $1.81M sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in NBIX in Q2 2013 and held it in 34 quarters. The position peaked at $4.36M in Q2 2021. 428 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 21,304 Neurocrine Biosciences shares in Q1 2022, an estimated $1.81M.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 34 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Neurocrine Biosciences position peaked at $4.36M in Q2 2021.
- 428 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.